Skip to main content
SpringerLink
Log in
Book cover

Perioperative Addiction pp 111–128Cite as

Club Drugs

  • Chapter
  • First Online:

  • 920 Accesses

Abstract

The use of illicit substances in large dance parties (“raves”) and nightclubs has become commonplace globally since the 1990s. Having now dispersed from rave sub-cultures, these drugs are available in college bars, house parties, and at concerts. Given this widespread availability, the “typical” club drug user is harder to classify than it had been in the 1990s. One large survey of New York City nightclub attendees attempted to characterize typical users: [1] 1,914 club-going adults aged 18–29 were sampled, of which 70% reported using club drugs at least once and 22% reported recent use. Men were more likely to abuse ketamine and GHB, while female gender was predictive of cocaine use. Gay/bisexual orientation and White race were predictive of use of several club drugs.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kelly BC, Parsons JT, Wells BE. Prevalence and predictors of club drug use among club-going young adults in New York City. J Urban Health. 2006;83(5):884–95.

    Article  PubMed  Google Scholar 

  2. European Monitoring Centre for Drugs and Drug addiction. The state of the drugs problem in the European Union and Norway: Annual report; 2007.

    Google Scholar 

  3. US Department of Heath and Human Services. National survey on drug use and health. Washington, DC: US Department of Health and Human Services; 2005.

    Google Scholar 

  4. National Institute on Drug Abuse. The monitoring the future national results on adolescent drug use: overview of key findings, 2001. Ann Arbor, MI: University of Michigan Institute for Social Research; 2002.

    Google Scholar 

  5. Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 2001;21(12):1486–513.

    Article  PubMed  CAS  Google Scholar 

  6. Suarez RV, Riemersma R. “Ecstasy” and sudden cardiac death. Am J Forensic Med Pathol. 1988;9:339–41.

    Article  PubMed  CAS  Google Scholar 

  7. Shulgin AT. The background and chemistry of MDMA. J Psychoactive Drugs. 1986;18:291–304.

    PubMed  CAS  Google Scholar 

  8. Greer GR, Tolbert R. A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs. 1998;30(4):371–9.

    Article  PubMed  CAS  Google Scholar 

  9. Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18:319–27.

    PubMed  CAS  Google Scholar 

  10. Wolff K, Hay AWM, Sherlock K, Conner M. Contents of “ecstasy”. Lancet. 1995;346:1100–1.

    Article  PubMed  CAS  Google Scholar 

  11. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl). 2000;152:230–48.

    Article  CAS  Google Scholar 

  12. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5:79–86.

    Article  PubMed  CAS  Google Scholar 

  13. Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav. 1988;29(2):269–74.

    Article  PubMed  CAS  Google Scholar 

  14. Oesterheld JR, Armstrong SC, Cozza KL. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics. 2004;45:84–7.

    Article  PubMed  CAS  Google Scholar 

  15. Ferigolo M, Machado AGS, Oliveira NB, et al. Ecstasy intoxication: the toxicological basis for treatment. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:332–41.

    Article  PubMed  Google Scholar 

  16. Cami J, Farre M, Mas M. Human pharmacology of 3,4- methylenedioxymethamphetamine (“Ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20:455–66.

    Article  PubMed  CAS  Google Scholar 

  17. Mas M, Farre M, de la Torre R. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136–45.

    PubMed  CAS  Google Scholar 

  18. Peroutka SJ. Incidence of recreational use of 3,4- methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on an undergraduate campus. N Engl J Med. 1987;317:1542–3.

    PubMed  CAS  Google Scholar 

  19. Cohen RS. Subjective reports on the effects of the MDMA (‘Ecstasy’) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19:1137–45.

    Article  PubMed  CAS  Google Scholar 

  20. O’Cain PA, Hletko SB, Ogden BA, et al. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav. 2000;70:141–8.

    Article  PubMed  Google Scholar 

  21. Walsh T, Carmichale R, Chestnut J. A hyperthermic reaction to ecstasy. Br J Hosp Med. 1994;51:476.

    PubMed  CAS  Google Scholar 

  22. Gill JR, Hayes JA, de Souza IS, et al. Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci. 2002;47:121–6.

    PubMed  Google Scholar 

  23. Logan ASC, Stickle B, O’Keefe N, Hewitson H. Survival following ‘Ecstasy’ ingestion with a peak temperature of 42°C. Anaesthesia. 1993;48:1017–8.

    Article  PubMed  CAS  Google Scholar 

  24. Hall AP. “Ecstasy” and the anaesthetist. Br J Anaesth. 1997;79:697–8.

    PubMed  CAS  Google Scholar 

  25. Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with “Ecstasy” and “Eve” misuse. J Clin Pathol. 1996;49:149–53.

    Article  PubMed  CAS  Google Scholar 

  26. Schmidt CJ, Black CK, Abbate GM, Taylor VL. MDMA induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85–90.

    Article  PubMed  CAS  Google Scholar 

  27. Nimmo SM, Kennedy BW, Tullett WM, Blyth AS, Dougall JR. Drug-induced hyperthermia. Anaesthesia. 1993;48(10):892–5.

    Article  PubMed  CAS  Google Scholar 

  28. Benowitz NL. Amphetamines. In: Olson KR, editor. Poisoning and drug overdose. 3rd ed. Stamford, CT: Appleton & Lange; 1999. p. 68–70.

    Google Scholar 

  29. Fiege M, Wappler F, Weisshorn R, et al. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine (“ecstasy”). Anesthesiology. 2003;99:1132–6.

    Article  PubMed  CAS  Google Scholar 

  30. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89(6):1277–96.

    Article  PubMed  CAS  Google Scholar 

  31. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627–33.

    Article  PubMed  CAS  Google Scholar 

  32. Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.

    Article  PubMed  CAS  Google Scholar 

  33. Ghuran A, van Der Wieken LR, Nolan J. Cardiovascular complications of recreational drugs. BMJ. 2001;323:464–6.

    Article  PubMed  CAS  Google Scholar 

  34. Brody S, Krause C, Veit R, Rau H. Cardiovascular autonomic dysregulation in users of MDMA (“Ecstasy”). Psychopharmacology. 1998;136:390–3.

    Article  PubMed  CAS  Google Scholar 

  35. Kessel B. Hyponatraemia after ingestion of “Ecstasy”. BMJ. 1994;308:414.

    Article  PubMed  CAS  Google Scholar 

  36. Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “Ecstasy” (3,4-MDMA) [letter]. Lancet. 1996;347:1052.

    Article  PubMed  CAS  Google Scholar 

  37. Henry JA, Fallon JK, Kicman AT. Low-dose MDMA (“Ecstasy”) induces vasopressin secretion [letter]. Lancet. 1998;351:1784.

    Article  PubMed  CAS  Google Scholar 

  38. Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (“Ecstasy”) usage. J Clin Gastroenterol. 1995;20:244–7.

    Article  PubMed  CAS  Google Scholar 

  39. Brauer RB, Heidecke CD, Nathrath W, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int. 1997;10:229–33.

    Article  PubMed  CAS  Google Scholar 

  40. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454–8.

    Article  PubMed  CAS  Google Scholar 

  41. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in Ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther. 1999;13:129–33.

    Article  PubMed  CAS  Google Scholar 

  42. Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry. 1993;56(9):1036–7.

    Article  PubMed  CAS  Google Scholar 

  43. Manchanda S, Connolly MJ. Cerebral infarction in association with ecstasy abuse. Postgrad Med. 1993;69:874–89.

    Article  CAS  Google Scholar 

  44. McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449–54.

    Article  PubMed  CAS  Google Scholar 

  45. McCann UD, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’). Drug Saf. 1996;15:107–15.

    Article  PubMed  CAS  Google Scholar 

  46. Ranalli E, Bouton R. Intracerebral haemorrhage associated with ingestion of “Ecstasy” [abstr]. Eur Neuropsychopharmacol. 1997;7:S263.

    Article  Google Scholar 

  47. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence? Drug Alcohol Depend. 2010;107(1):1–10.

    Article  PubMed  CAS  Google Scholar 

  48. Klein M, Kramer F. Rave drugs: pharmacological considerations. AANA J. 2004;72:61–7.

    PubMed  Google Scholar 

  49. Reneman L, Habraken JB, Majoie CB, et al. MDMA (“Ecstasy”) and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol. 2000;21:1001–7.

    PubMed  CAS  Google Scholar 

  50. Richards JR. Rhabdomyolisis and drugs abuse. J Emerg Med. 2000;19:51–6.

    Article  PubMed  CAS  Google Scholar 

  51. Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia. 1992;47:686–7.

    Article  PubMed  CAS  Google Scholar 

  52. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63:1–22.

    Article  PubMed  CAS  Google Scholar 

  53. Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of “club drugs”. Subst Use Misuse. 2005;40:1189–201.

    Article  PubMed  Google Scholar 

  54. Okun M, Bartfield RB, Doering PL. GHB toxicity: what you need to know. Emerg Med. 2000;10–23.

    Google Scholar 

  55. Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid: efficacy, potential abuse and dependence in the treatment of alcohol addiction. Alcohol. 2000;20:217–22.

    Article  PubMed  CAS  Google Scholar 

  56. Halkitis PN, Palamar JJ. GHB use among gay and bisexual men. Addict Behav. 2006;31(11):2135–9.

    Article  PubMed  Google Scholar 

  57. Knudsen K, Greter J, Verdicchio M, et al. A severe outburst of GHB poisonings (gamma-hydroxybutyrate, gamma-hydroxybutyric acid) on the West Coast of Sweden. Mortality numbers ahead of heroin. Clin Toxicol. 2006;44(5):637–8.

    Google Scholar 

  58. Tunnicliff G. Sites of action of gamma-hydroxybutyrate – a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35(6):581–90.

    Article  PubMed  CAS  Google Scholar 

  59. Hedou G, Chasserot-Golaz S, Kemmel V, Gobaille S, Roussel G, Artault JC, et al. Immunohistochemical studies of the localization of neurons containing the enzyme that synthesizes dopamine, GABA, or gamma-hydroxybutyrate in the rat substantia nigra and striatum. J Comp Neurol. 2000;426(4):549–60.

    Article  PubMed  CAS  Google Scholar 

  60. Graeme KA. New drugs of abuse. Emerg Med Clin North Am. 2000;18:625–36.

    Article  PubMed  CAS  Google Scholar 

  61. Galloway GP, Frederick SL, Staggers Jr F. Physical dependence on sodium oxybate. Lancet. 1994;343(8888):57.

    Article  PubMed  CAS  Google Scholar 

  62. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat. 2002;23:151–6.

    Article  PubMed  Google Scholar 

  63. McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies. J Psychoactive Drugs. 2001;33(2):143–9.

    Article  PubMed  CAS  Google Scholar 

  64. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37:147–53.

    Article  PubMed  CAS  Google Scholar 

  65. Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7:278–81.

    Article  PubMed  CAS  Google Scholar 

  66. Rome ES. It’s a rave new world: rave culture and illicit drug use in the young. Clev Clin J Med. 2001;68:541–50.

    Article  CAS  Google Scholar 

  67. Berti M, Baciarello M, Troglio R, Fanelli G. Clinical uses of low-dose ketamine in patients undergoing surgery. Curr Drug Targets. 2009;10(8):707–15.

    Article  PubMed  CAS  Google Scholar 

  68. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30(11):563–9.

    Article  PubMed  CAS  Google Scholar 

  69. Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs. 2001;33:151–8.

    Article  PubMed  CAS  Google Scholar 

  70. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186–93.

    PubMed  CAS  Google Scholar 

  71. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36(2):186–97.

    Article  PubMed  CAS  Google Scholar 

  72. Weiner AL, Viera L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med. 2000;18:447–51.

    Article  PubMed  CAS  Google Scholar 

  73. Pal HR, Berry N, Kumar R, et al. Ketamine dependence. Anaesth Intensive Care. 2002;30:382–4.

    PubMed  CAS  Google Scholar 

  74. Ricaurtie GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet. 2005;365:2137–45.

    Article  Google Scholar 

  75. Yu Q, Montes S, Larson D, Watson RR. Effects of chronic methamphetamine exposure on heart function in uninfected and retrovirus-infected mice. Life Sci. 1995;75:29–43.

    Google Scholar 

  76. National Institute on Drug Abuse, Methamphetamine Abuse and addiction: what is Methamphetamine? Bethesda, MD: National Institute of Health; 1998. NIDA research report series, NIH publication 98-4210.

    Google Scholar 

  77. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377–82.

    Article  PubMed  CAS  Google Scholar 

  78. Karch SB, Stephens BG, Ho CH. Methamphetamine related deaths in San Francisco; demographic, pathologic and toxicologic profiles. J Forensic Sci. 1999;44:359–68.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Mount Sinai School of Medicine, New York, NY, USA

    Samuel DeMaria Jr. MD

Authors
  1. Samuel DeMaria Jr. MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel DeMaria Jr. MD .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, Mount Sinai School of Medicine, Associate Professor, New York, 10029, New York, USA

    Ethan O. Bryson

  2. Department of Anesthesiology, Mount Sinai School of Medicine, Professor, New York, 10029, New York, USA

    Elizabeth A. M. Frost

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

DeMaria, S. (2012). Club Drugs. In: Bryson, E., Frost, E. (eds) Perioperative Addiction. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0170-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0170-4_6

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-0169-8

  • Online ISBN: 978-1-4614-0170-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation